FY2025 EPS Estimates for NeuroPace Lifted by Leerink Partnrs

NeuroPace, Inc. (NASDAQ:NPCE) – Research analysts at Leerink Partnrs upped their FY2025 earnings per share estimates for NeuroPace in a research report issued to clients and investors on Tuesday, August 12th. Leerink Partnrs analyst M. Kratky now anticipates that the company will post earnings per share of ($0.80) for the year, up from their previous forecast of ($0.83). The consensus estimate for NeuroPace’s current full-year earnings is ($1.00) per share. Leerink Partnrs also issued estimates for NeuroPace’s Q4 2025 earnings at ($0.14) EPS, FY2026 earnings at ($0.29) EPS, FY2027 earnings at ($0.02) EPS and FY2028 earnings at $0.28 EPS.

NeuroPace (NASDAQ:NPCE) last posted its quarterly earnings data on Tuesday, August 12th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.24) by ($0.02). NeuroPace had a negative return on equity of 168.61% and a negative net margin of 29.29%. The company had revenue of $23.52 million during the quarter, compared to the consensus estimate of $23.08 million.

Several other research analysts also recently commented on the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $17.00 price objective on shares of NeuroPace in a research note on Wednesday, May 14th. JPMorgan Chase & Co. lifted their target price on NeuroPace from $14.00 to $16.00 and gave the company an “overweight” rating in a research note on Wednesday, May 14th. Wells Fargo & Company decreased their target price on NeuroPace from $17.00 to $15.00 and set an “overweight” rating on the stock in a research note on Wednesday. Finally, HC Wainwright assumed coverage on NeuroPace in a research note on Wednesday, May 28th. They set a “buy” rating and a $18.00 target price on the stock. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and an average price target of $16.60.

NeuroPace Stock Down 5.2%

NASDAQ NPCE opened at $8.56 on Friday. The stock’s 50-day moving average price is $9.91 and its 200-day moving average price is $11.72. The company has a quick ratio of 5.70, a current ratio of 5.47 and a debt-to-equity ratio of 3.02. NeuroPace has a 52 week low of $5.45 and a 52 week high of $18.98. The company has a market capitalization of $283.16 million, a P/E ratio of -10.19 and a beta of 1.89.

Institutional Trading of NeuroPace

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Ameritas Investment Partners Inc. grew its holdings in NeuroPace by 83.6% during the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,455 shares of the company’s stock valued at $27,000 after buying an additional 1,118 shares in the last quarter. Legal & General Group Plc grew its holdings in NeuroPace by 86.0% during the 2nd quarter. Legal & General Group Plc now owns 2,679 shares of the company’s stock valued at $30,000 after buying an additional 1,239 shares in the last quarter. Rhumbline Advisers grew its holdings in NeuroPace by 15.2% during the 1st quarter. Rhumbline Advisers now owns 17,227 shares of the company’s stock valued at $212,000 after buying an additional 2,267 shares in the last quarter. Wells Fargo & Company MN grew its holdings in NeuroPace by 54.2% during the 4th quarter. Wells Fargo & Company MN now owns 6,483 shares of the company’s stock valued at $73,000 after buying an additional 2,279 shares in the last quarter. Finally, BNP Paribas Financial Markets purchased a new position in NeuroPace during the 4th quarter valued at approximately $29,000. Institutional investors own 78.83% of the company’s stock.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.